BusinessEsperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial ResultsBy Nasdaq OMXMay 4, 2017, 8:07 PM UTC
BusinessEsperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial ResultsBy Nasdaq OMXMay 4, 2017, 8:06 PM UTC
BusinessEsperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic AcidBy Nasdaq OMXMar 20, 2017, 11:30 AM UTC
BusinessEsperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/AtorvastatinBy Nasdaq OMXMar 7, 2017, 1:31 PM UTC
BusinessEsperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/AtorvastatinBy Nasdaq OMXMar 7, 2017, 1:30 PM UTC
BusinessEsperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic AcidBy Nasdaq OMXJan 8, 2017, 9:00 PM UTC
BusinessEsperion to Present at the 35th Annual J.P. Morgan Healthcare ConferenceBy Nasdaq OMXJan 4, 2017, 10:00 PM UTC
BusinessEsperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature CommunicationsBy Nasdaq OMXNov 28, 2016, 9:30 PM UTC
